Epitomee Medical Ltd. Logo

Epitomee Medical Ltd.

Develops ingestible therapeutic devices for chronic diseases.

EPIT | TA

Overview

Corporate Details

ISIN(s):
IL0011825911
LEI:
Country:
Israel
Address:
17 Hatochen, 3079892 Caesarea

Description

Epitomee Medical Ltd. develops and commercializes ingestible therapeutic devices for chronic diseases. The company's core technology is a platform based on a self-administered, swallowable capsule that deploys targeted therapies along the gastrointestinal (GI) tract. These devices are engineered for controlled activation in specific regions, such as the stomach or small intestine, to provide mechano-sensory stimulation, targeted drug delivery, or absorption management. The therapies have a predetermined duration of activity, after which the device dissolves and is passed naturally. The company's flagship product is an FDA-cleared, drug-free weight management capsule. Epitomee is also advancing a platform for the oral delivery of biologic drugs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-11-30 10:58
Investor Presentation
Hebrew (modern) 1.1 MB
2023-11-30 10:58
Investor Presentation
Russian 42.4 KB
2023-09-12 10:37
Presentation- September 2023
English 2.4 MB
2023-09-12 10:37
Presentation- September 2023
Russian 42.1 KB
2022-03-29 13:15
TASE Indices – Epitomee Med Factor Correction
Hebrew (modern) 158.0 KB
2022-02-17 19:30
Will be added to the respective indices thru the fast track on March 3rd , 2022…
Hebrew (modern) 327.0 KB
2021-12-21 18:44
Will be add to the TA-Tech Elite Index On March 3rd, 2021 thru the Fast Track
Hebrew (modern) 161.3 KB
2021-12-14 16:03
Opening of Trading On December 15 2021-EPITOMEE MED
Hebrew (modern) 175.6 KB
2021-12-14 15:03
Opening of Trading On December 15 2021-EPITOMEE MED
Hebrew (modern) 175.6 KB
2021-12-13 12:45
Identifying Details of New Security- EPITOMEE MED
Hebrew (modern) 174.7 KB
2021-11-29 18:33
Investor Presentation-November 2021
English 2.8 MB
2021-11-29 18:33
Investor Presentation-November 2021
Russian 41.6 KB

Automate Your Workflow. Get a real-time feed of all Epitomee Medical Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Epitomee Medical Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Epitomee Medical Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.